Meeting
2017 Genitourinary Cancers Symposium
Effects of radium-223 (Ra-223) with docetaxel versus docetaxel alone on bone biomarkers in patients with bone-metastatic castration-resistant prostate cancer (CRPC): A phase I/IIa clinical trial.
Authors
Michael J. Morris
Memorial Sloan Kettering Cancer Center, New York, NY
Michael J. Morris , Yohann Loriot , Karim Fizazi , Christopher Sweeney , Charles J. Ryan , Daniel H. Shevrin , Emmanuel S. Antonarakis , Monica Seger , Chengxing Lu , Celestia S. Higano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT01106352
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 154)
DOI
10.1200/JCO.2017.35.6_suppl.154
Abstract #
154
Poster Bd #
F8
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Relationship of bone scan index and progression-free survival after docetaxel treatment for CRPC patients with bone metastases.
First Author: Atsushi Mizokami
Poster
2021 ASCO Annual Meeting
Biomarker analysis of phase (Ph) IB trial of radium-223 (Rad) and niraparib (Nira) in patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) (NiraRad).
First Author: Eddy Shih-Hsin Yang
Poster
2020 Genitourinary Cancers Symposium
Gene expression in circulating tumor cells (CTC) and plasma androgen receptor (AR) gene copy number (CN) for castration-resistant prostate cancer (CRPC) patients (pts) treated with cabazitaxel.
First Author: Giorgia Gurioli
Poster
2016 Genitourinary Cancers Symposium
Interrogating metastatic prostate cancer treatment switch decisions.
First Author: David Lorente